These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1055 related articles for article (PubMed ID: 29724224)

  • 1. MOG encephalomyelitis: international recommendations on diagnosis and antibody testing.
    Jarius S; Paul F; Aktas O; Asgari N; Dale RC; de Seze J; Franciotta D; Fujihara K; Jacob A; Kim HJ; Kleiter I; Kümpfel T; Levy M; Palace J; Ruprecht K; Saiz A; Trebst C; Weinshenker BG; Wildemann B
    J Neuroinflammation; 2018 May; 15(1):134. PubMed ID: 29724224
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [MOG encephalomyelitis: international recommendations on diagnosis and antibody testing].
    Jarius S; Paul F; Aktas O; Asgari N; Dale RC; de Seze J; Franciotta D; Fujihara K; Jacob A; Kim HJ; Kleiter I; Kümpfel T; Levy M; Palace J; Ruprecht K; Saiz A; Trebst C; Weinshenker BG; Wildemann B
    Nervenarzt; 2018 Dec; 89(12):1388-1399. PubMed ID: 30264269
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuromyelitis optica spectrum disorders with antibodies to myelin oligodendrocyte glycoprotein or aquaporin-4: Clinical and paraclinical characteristics in Algerian patients.
    Bouzar M; Daoudi S; Hattab S; Bouzar AA; Deiva K; Wildemann B; Reindl M; Jarius S
    J Neurol Sci; 2017 Oct; 381():240-244. PubMed ID: 28991690
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cerebrospinal fluid findings in patients with myelin oligodendrocyte glycoprotein (MOG) antibodies. Part 2: Results from 108 lumbar punctures in 80 pediatric patients.
    Jarius S; Lechner C; Wendel EM; Baumann M; Breu M; Schimmel M; Karenfort M; Marina AD; Merkenschlager A; Thiels C; Blaschek A; Salandin M; Leiz S; Leypoldt F; Pschibul A; Hackenberg A; Hahn A; Syrbe S; Strautmanis J; Häusler M; Krieg P; Eisenkölbl A; Stoffels J; Eckenweiler M; Ayzenberg I; Haas J; Höftberger R; Kleiter I; Korporal-Kuhnke M; Ringelstein M; Ruprecht K; Siebert N; Schanda K; Aktas O; Paul F; Reindl M; Wildemann B; Rostásy K;
    J Neuroinflammation; 2020 Sep; 17(1):262. PubMed ID: 32883358
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cerebrospinal fluid findings in patients with myelin oligodendrocyte glycoprotein (MOG) antibodies. Part 1: Results from 163 lumbar punctures in 100 adult patients.
    Jarius S; Pellkofer H; Siebert N; Korporal-Kuhnke M; Hümmert MW; Ringelstein M; Rommer PS; Ayzenberg I; Ruprecht K; Klotz L; Asgari N; Zrzavy T; Höftberger R; Tobia R; Buttmann M; Fechner K; Schanda K; Weber M; Asseyer S; Haas J; Lechner C; Kleiter I; Aktas O; Trebst C; Rostasy K; Reindl M; Kümpfel T; Paul F; Wildemann B;
    J Neuroinflammation; 2020 Sep; 17(1):261. PubMed ID: 32883348
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improving the sensitivity of myelin oligodendrocyte glycoprotein-antibody testing: exclusive or predominant MOG-IgG3 seropositivity-a potential diagnostic pitfall in patients with MOG-EM/MOGAD.
    Jarius S; Ringelstein M; Schanda K; Ruprecht K; Korporal-Kuhnke M; Viehöver A; Hümmert MW; Schindler P; Endmayr V; Gastaldi M; Trebst C; Franciotta D; Aktas O; Höftberger R; Haas J; Komorowski L; Paul F; Reindl M; Wildemann B
    J Neurol; 2024 Jul; 271(7):4660-4671. PubMed ID: 38609667
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic implications of MOG-IgG detection in sera and cerebrospinal fluids.
    Matsumoto Y; Kaneko K; Takahashi T; Takai Y; Namatame C; Kuroda H; Misu T; Fujihara K; Aoki M
    Brain; 2023 Sep; 146(9):3938-3948. PubMed ID: 37061817
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinicoradiological comparative study of Aquaporin-4-IgG seropositive neuromyelitis optica spectrum disorder (NMOSD) and MOG antibody associated disease (MOGAD): A prospective observational study and review of literature.
    Nagireddy RBR; Kumar A; Singh VK; Prasad R; Pathak A; Chaurasia RN; Mishra VN; Joshi D
    J Neuroimmunol; 2021 Dec; 361():577742. PubMed ID: 34655992
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of diagnostic criteria and red flags of myelin oligodendrocyte glycoprotein encephalomyelitis in a clinical routine cohort.
    Veselaj K; Kamber N; Briner M; Friedli C; Diem L; Guse K; Miclea A; Wiest R; Wagner F; Grabe H; Abegg M; Horn MP; Bigi S; Chan A; Hoepner R; Salmen A
    CNS Neurosci Ther; 2021 Apr; 27(4):426-438. PubMed ID: 33047894
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The clinical value of complement proteins in differentiating AQP4-IgG-positive from MOG-IgG-positive neuromyelitis optica spectrum disorders.
    Qin C; Chen B; Tao R; Chen M; Ma X; Shang K; Wu LJ; Wang W; Bu BT; Tian DS
    Mult Scler Relat Disord; 2019 Oct; 35():1-4. PubMed ID: 31276911
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: Frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin.
    Jarius S; Ruprecht K; Kleiter I; Borisow N; Asgari N; Pitarokoili K; Pache F; Stich O; Beume LA; Hümmert MW; Trebst C; Ringelstein M; Aktas O; Winkelmann A; Buttmann M; Schwarz A; Zimmermann H; Brandt AU; Franciotta D; Capobianco M; Kuchling J; Haas J; Korporal-Kuhnke M; Lillevang ST; Fechner K; Schanda K; Paul F; Wildemann B; Reindl M;
    J Neuroinflammation; 2016 Sep; 13(1):279. PubMed ID: 27788675
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Myelin oligodendrocyte glycoprotein immunoglobulin G-associated encephalomyelitis].
    Eliseeva DD; Vasiliev AV; Shabalina AA; Simaniv TO; Zakharova MN
    Zh Nevrol Psikhiatr Im S S Korsakova; 2020; 120(7. Vyp. 2):13-23. PubMed ID: 32844625
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Update on the diagnosis and treatment of neuromyelits optica spectrum disorders (NMOSD) - revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part I: Diagnosis and differential diagnosis.
    Jarius S; Aktas O; Ayzenberg I; Bellmann-Strobl J; Berthele A; Giglhuber K; Häußler V; Havla J; Hellwig K; Hümmert MW; Kleiter I; Klotz L; Krumbholz M; Kümpfel T; Paul F; Ringelstein M; Ruprecht K; Senel M; Stellmann JP; Bergh FT; Tumani H; Wildemann B; Trebst C;
    J Neurol; 2023 Jul; 270(7):3341-3368. PubMed ID: 37022481
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Aquaporin 4 antibody-positive neuromyelitis optica spectrum disorders and myelin oligodendrocyte glycoprotein antibody-associated encephalomyelitis. A brief review].
    Jarius S; Wildemann B
    Nervenarzt; 2021 Apr; 92(4):317-333. PubMed ID: 33787942
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Characteristics and Treatment of MOG-IgG-Associated Optic Neuritis.
    Tajfirouz DA; Bhatti MT; Chen JJ
    Curr Neurol Neurosci Rep; 2019 Nov; 19(12):100. PubMed ID: 31773369
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MOG encephalomyelitis: distinct clinical, MRI and CSF features in patients with longitudinal extensive transverse myelitis as first clinical presentation.
    Loos J; Pfeuffer S; Pape K; Ruck T; Luessi F; Spreer A; Zipp F; Meuth SG; Bittner S
    J Neurol; 2020 Jun; 267(6):1632-1642. PubMed ID: 32055995
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical phenotype, radiological features, and treatment of myelin oligodendrocyte glycoprotein-immunoglobulin G (MOG-IgG) optic neuritis.
    Chen JJ; Bhatti MT
    Curr Opin Neurol; 2020 Feb; 33(1):47-54. PubMed ID: 31743235
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Myelin-oligodendrocyte-glycoprotein (MOG) autoantibodies as potential markers of severe optic neuritis and subclinical retinal axonal degeneration.
    Havla J; Kümpfel T; Schinner R; Spadaro M; Schuh E; Meinl E; Hohlfeld R; Outteryck O
    J Neurol; 2017 Jan; 264(1):139-151. PubMed ID: 27844165
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome.
    Jarius S; Ruprecht K; Kleiter I; Borisow N; Asgari N; Pitarokoili K; Pache F; Stich O; Beume LA; Hümmert MW; Ringelstein M; Trebst C; Winkelmann A; Schwarz A; Buttmann M; Zimmermann H; Kuchling J; Franciotta D; Capobianco M; Siebert E; Lukas C; Korporal-Kuhnke M; Haas J; Fechner K; Brandt AU; Schanda K; Aktas O; Paul F; Reindl M; Wildemann B;
    J Neuroinflammation; 2016 Sep; 13(1):280. PubMed ID: 27793206
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnostic features of initial demyelinating events associated with serum MOG-IgG.
    Orlandi R; Mariotto S; Ferrari S; Gobbin F; Sechi E; Capra R; Mancinelli CR; Bombardi R; Zuliani L; Zoccarato M; Rossi F; Camera V; Ferraro D; Benedetti MD; Reindl M; Gajofatto A
    J Neuroimmunol; 2020 Jul; 344():577260. PubMed ID: 32442864
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 53.